Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pfizer (PFE)
NYSE:PFE
Holding PFE?
Track your performance easily
PFE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.20 - $31.54
Previous Close$28.45
Volume26.09M
Average Volume (3M)30.42M
Market Cap
$161.22B
Enterprise Value$223.84B
Total Cash (Recent Filing)$7.10B
Total Debt (Recent Filing)$69.45B
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Oct 29, 2024EPS Estimate
$0.61Next Dividend Ex-Date
Nov 08, 2024Dividend Yield5.87%
Share Statistics
EPS (TTM)-0.46
Shares Outstanding5,666,695,064
10 Day Avg. Volume26,105,974
30 Day Avg. Volume30,416,454
Standard Deviation0.08
R-Squared0.19
Alpha-0.00468
Financial Highlights & Ratios
Price to Book (P/B)1.84
Price to Sales (P/S)2.90
Price to Cash Flow (P/CF)-22.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit6.67
Enterprise Value/Ebitda28.01
Forecast
1Y Price Target
$32.47Price Target Upside14.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Pfizer News
PremiumStock Analysis & Ideas
Is Pfizer (NYSE:PFE) a High-Yielding Dividend Stock Worth Buying?
PremiumStock Analysis & Ideas
Is Moderna (NASDAQ:MRNA) Stock a Buy at Current Levels?
Bulls Say, Bears Say
Bulls Say
COVID-19 Vaccine SalesEarlier COVID surge & vaccinations could pull forward COVID sales to Q3, resulting in $250M upside to consensus.
Product PotentialPonsegromab offers blockbuster potential since there is no approved treatment for cancer cachexia in the U.S. or Europe.
Shareholder ConfidenceFormer Pfizer executives support the current leadership and expect them to create shareholder value over time.
Bears Say
Clinical Trials And Drug DevelopmentPfizer had to discontinue the development of lotiglipron due to liver toxicity concerns.
Financial PerformanceDespite significant cost-cutting measures, Pfizer is not expected to generate significant earnings growth post-2027, with revenues predicted to be flat or declining.
Vaccine SalesOther vaccines could be weak, as Abrysvo sales could miss by $40M due to recent surge in COVID vaccinations putting pressure on RSV vaccine demand.
---
Ownership Overview
0.03% Insiders
19.00% Mutual Funds
1.59% Other Institutional Investors
57.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PFE FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was $25.20 and its highest was $31.54 in the past 12 months.
What is Pfizer’s market cap?
Currently, no data Available
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Oct 29, 2024 which is 6 days ago.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Jul 30, 2024. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of $0.458 by $0.142.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of $0.42 which represents an annual dividend yield of 5.87%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is $0.61.
How many shares outstanding does Pfizer have?
Pfizer has 5,666,695,000 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.6 in its last earnings report, beating expectations of $0.458. Following the earnings report the stock price went up 2.181%.
Which hedge fund is a major shareholder of Pfizer?
Among the largest hedge funds holding Pfizer’s share is Diamond Hill Capital Management Inc. It holds Pfizer’s shares valued at 445M.
---
Pfizer Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.47 (14.13% Upside)
$32.47 (14.13% Upside)
Blogger Sentiment
Bullish
PFE Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $147.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.95%
12-Months-Change
Fundamentals
Return on Equity
-2.78%
Trailing 12-Months
Asset Growth
-1.81%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
---
PFE Company Deck
---
PFE Earnings Call
Q2 2024
0:00 / 0:00
---
PFE Revenue Breakdown
52.29% Primary Care
25.59% Specialty Care
19.88% Oncology
2.24% BUSINESS INNOVATION
---
PFE Stock 12 Month Forecast
Average Price Target
$32.47
▲(14.13% Upside)
Technical Analysis
Best Analysts Covering PFE
1 Year
1 Year Success Rate
26/34 ratings generated profit
1 Year Average Return
+5.71%
initiated a buy rating 9 months ago
Copying Vamil Divan's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +5.71% per trade.
---